Company Encyclopedia
View More
name
Xinguang Pharma
300519.SZ
Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health food in China. It offers pharmaceutical products that cover respiratory, digestive, and urinary systems, as well as cardiovascular, cerebrovascular, trauma, and pediatric diseases. The company was incorporated in 1998 and is headquartered in Shengzhou, China.
3.144 T
300519.SZMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking170/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.04%C
    • Profit Margin22.54%A
    • Gross Margin44.96%B
  • Growth ScoreC
    • Revenue YoY-4.97%D
    • Net Profit YoY33.39%B
    • Total Assets YoY0.11%C
    • Net Assets YoY1.23%C
  • Cash ScoreC
    • Cash Flow Margin443.65%C
    • OCF YoY-4.97%D
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreA
    • Gearing Ratio7.33%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Xinguang Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 45.3362 million yuan, an increase of 19.99%

    Xinguang Pharma released its third-quarter report for 2025, with operating revenue of 206 million yuan in the first three quarters, a year-on-year decrease of 4.90%. The net profit attributable to the parent company was 45.3362 million yuan, a year-on-year increase of 19.99%; the net profit excluding non-recurring gains and losses was 43.4886 million yuan, a year-on-year increase of 25.86%. The basic earnings per share were 0.28 yuan

    Zhitong·
    SZ
    300519
    -2.42%
    Zhitong·
    SZ
    300519
    -2.42%

    Xinguang Pharma's shareholder, Feng Investment, plans to reduce its holdings by no more than 3%

    According to the Zhitong Finance APP, Xinguang Pharma announced that its shareholder, Shengzhou Hefeng Investment Co., Ltd. ("Hefeng Investment"), plans to reduce its holdings of no more than 4.8 million shares of the company (i.e., no more than 3% of the company's total share capital) through centralized bidding or block trading within 3 months after 15 trading days from the date of this announcement

    Zhitong·
    SZ
    300519
    -2.42%
    Zhitong·
    SZ
    300519
    -2.42%

    Xinguang Pharma released its first-quarter performance, with a net profit attributable to the parent company of 24.5418 million yuan, an increase of 7.50%

    Xinguang Pharma released its Q1 2025 performance report, with operating revenue of 93.2501 million yuan, a year-on-year decrease of 7.26%. The net profit attributable to the parent company was 24.5418 million yuan, a year-on-year increase of 7.50%. The net profit after deducting non-recurring gains and losses was 23.3665 million yuan, a year-on-year increase of 9.49%. The basic earnings per share were 0.15 yuan

    Zhitong·
    SZ
    300519
    -2.42%
    Zhitong·
    SZ
    300519
    -2.42%

    Xinguang Pharma released its 2024 annual performance, with a net profit attributable to the parent company of 50.39 million yuan, a decrease of 21.70%

    Xinguang Pharma released its 2024 annual report, with operating revenue of 268 million yuan, a year-on-year decrease of 1.01%; net profit attributable to shareholders was 50.39 million yuan, a year-on-year decline of 21.70%; net profit excluding non-recurring gains and losses was 45.394 million yuan, a year-on-year decrease of 24.50%. The basic earnings per share were 0.31 yuan, and it plans to distribute a cash dividend of 3.00 yuan (tax included) for every 10 shares to all shareholders

    Zhitong·
    SZ
    300519
    -2.42%
    Zhitong·
    SZ
    300519
    -2.42%

    Xinguang Pharma: The company currently has no innovative drugs participating in centralized procurement

    On April 9th, Xinguang Pharma stated on the interactive platform that the company currently has no innovative drugs participating in centralized procurement

    Zhitong·
    SZ
    300519
    -2.42%
    Zhitong·
    SZ
    300519
    -2.42%
    © 2025 Longbridge｜Disclaimer